Top Page
BrainChip Holdings
(OTC:BRN)
BrainChip Holdings (BRN) vs. iShares MSCI Australia ETF (EWA)
BrainChip Holdings Business Overview & Revenue Model
BrainChip Holdings Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.95M | 398.01K | 232.00K | 5.07M | 1.59M |
| Gross Profit | -2.59M | -134.91K | 91.44K | 4.59M | 1.30M |
| EBITDA | -19.53M | -23.67M | -27.99M | -21.41M | -20.65M |
| Net Income | -21.18M | -24.43M | -28.88M | -22.09M | -20.98M |
Balance Sheet | |||||
| Total Assets | 34.17M | 23.05M | 20.18M | 29.18M | 23.78M |
| Cash, Cash Equivalents and Short-Term Investments | 31.73M | 20.00M | 14.34M | 23.12M | 19.37M |
| Total Debt | 1.18M | 1.17M | 1.70M | 2.05M | 1.85M |
| Total Liabilities | 3.46M | 3.22M | 3.35M | 5.46M | 4.84M |
| Stockholders Equity | 30.71M | 19.83M | 16.83M | 23.72M | 18.94M |
Cash Flow | |||||
| Free Cash Flow | -16.02M | -15.96M | -17.66M | -19.88M | -13.94M |
| Operating Cash Flow | -15.98M | -15.88M | -17.53M | -19.69M | -13.69M |
| Investing Cash Flow | -2.09M | -72.65K | -132.60K | -127.22K | -265.55K |
| Financing Cash Flow | 29.38M | 22.60M | 8.84M | 17.59M | 14.69M |
BrainChip Holdings Technical Analysis
BrainChip Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | AU$36.40M | -77.51 | 4.70% | 4.66% | 14.59% | -11.13% | |
59 Neutral | AU$980.95M | -8.87 | -57.61% | ― | 333.23% | 10.83% | |
48 Neutral | AU$312.35M | -11.70 | -89.98% | ― | 503.29% | 11.46% | |
43 Neutral | AU$22.67M | -6.20 | -112.59% | ― | ― | -67.74% |
BrainChip Holdings Corporate Events
BrainChip Holdings has clarified an earlier statement, correcting a typographical error to confirm it produces neuromorphic AI IP, silicon and reference designs, rather than “silicone,” underscoring its positioning at the forefront of low‑power edge AI hardware. The company also announced that its Annual General Meeting will be held on 6 May 2026 in Sydney, with written director nominations, including the nominee’s consent, due by close of business on 12 March 2026, signalling the next key governance milestone for shareholders.
Further details for investors about the AGM will be provided in a forthcoming Notice of Meeting, which will outline resolutions and logistics for participation. The update reinforces BrainChip’s corporate governance processes at a time when its neuromorphic Akida technology and temporal event‑based neural network solutions are being promoted as enabling real‑time, energy‑efficient AI at the edge, potentially influencing its strategic direction and board composition.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip has scheduled its 2026 Annual General Meeting for 6 May in Sydney, and set 12 March as the deadline for shareholders to submit written nominations for board seats with the consent of proposed directors. The formal meeting notice will follow, and the AGM process underscores ongoing governance and board renewal at the neuromorphic Edge AI specialist as it advances commercial deployment of its Akida technology across multiple industries.
The timetable for director nominations provides clarity for investors and potential board candidates ahead of the May meeting, where shareholders will help shape the company’s leadership. This governance milestone comes as BrainChip positions its ultra-low power AI IP and processors for broader adoption at the network edge, a segment attracting growing interest from industrial, automotive, and consumer technology stakeholders.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings has disclosed a change in the holdings of director Peter Van Der Made, following the vesting and lapse of performance rights granted to him. As a result of the vesting, he received 171,722 fully paid ordinary shares at no cash consideration, while 429,302 performance rights were disposed of, increasing his total direct shareholding to 156,977,545 shares.
The transaction did not involve any trading during a closed period and required no disclosure of interests in separate contracts. The adjustment reflects routine equity-based remuneration mechanics rather than a market purchase or sale, clarifying the director’s updated equity stake and maintaining transparency for shareholders under ASX disclosure rules.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings has disclosed changes in the equity interests of director Sean Hehir, reflecting the vesting of restricted stock units and subsequent share transactions. Following these changes, Hehir’s holdings increased to 3,857,963 fully paid ordinary shares, while his restricted stock units decreased to 9,654,186.
The adjustments arose from the vesting and lapse of certain restricted stock units at no cash consideration, and an on-market sale of ordinary shares at $0.14 per share to fund U.S. federal and state tax obligations tied to the vesting event. The move underscores BrainChip’s continued use of equity-based remuneration for executives, which can affect share supply in the market but is broadly in line with standard governance and compensation practices.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings’ board has introduced a more disciplined investor relations framework aimed at improving transparency, consistency, and compliance with ASX continuous disclosure rules. The company is consolidating all external communications under a single board-approved policy and reducing informal channels in favor of structured, official disclosures.
The updated policy clarifies that BrainChip will focus announcements on price-sensitive information, binding contracts, material operational updates, and board-directed clarifications, while avoiding early-stage discussions and unverified projections. To keep investors better informed between major milestones, the company will add quarterly commercial progress summaries, interactive briefings with live Q&A, and standardized protocols for handling shareholder inquiries, reinforcing market integrity and equal access to information.
These changes signal a stronger governance stance that may bolster investor confidence and trust in the reliability of BrainChip’s market communications. The emphasis on global messaging consistency and prohibition of selective disclosure is designed to protect market integrity and support a more engaged and well-informed shareholder base.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings has lodged its updated corporate governance statement for the financial year ended 31 December 2025, confirming that the document is available on its investor website and has been approved by the board as of 18 February 2026. The filing, made via an Appendix 4G with the ASX, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, providing investors with greater transparency on board oversight, management accountability, and governance practices that underpin its operations.
The Appendix 4G also serves as a guide to where specific governance disclosures can be found and acts as a verification tool showing the company has met ASX disclosure requirements. By formally documenting its governance framework, including board charters, appointment processes and accountability of the company secretary, BrainChip reinforces its compliance credentials and supports shareholder confidence in its governance as it pursues growth in the AI technology sector.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip posted a sharp rise in revenue from continuing operations to US$1.89 million for the year to 31 December 2025, up 374% on the prior year, while narrowing its operating loss to US$21.71 million and after-tax loss to US$20.47 million. Results were supported by a swing to a US$1.31 million net finance and fair value gain, including foreign exchange and fair value movements, while loss per share improved and net tangible assets per share rose to 1.33 U.S. cents, even as the company maintained its no-dividend policy and reported an unqualified audit opinion.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.15 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip’s December 2025 quarter was marked by steady early-stage commercial traction and a strengthened balance sheet as it pushes to scale its neuromorphic AI platform. Customer cash inflows rose slightly to US$0.4 million while operating outflows fell to US$4.3 million, and the company bolstered liquidity to US$31.7 million following a fully underwritten A$35 million institutional placement and an oversubscribed share purchase plan, positioning it to fund commercialisation of its Akida technology and next-generation edge AI products. Operationally, BrainChip advanced a strategic multi-year partnership with Parsons’ Blue Ridge Envisioneering, including an initial 10,000-chip order and a supply framework geared to high-volume defence deployments, and it commenced volume production of its AKD1500 edge AI co-processor, which has been designed into solutions for defence and medical sensing and received a further order from Nex Novus. The AKD1500’s ultra-low power performance, compatibility with x86, ARM and RISC-V systems, and support for on-chip learning via BrainChip’s MetaTF toolchain and Akida architecture reinforce the company’s bid to capture share in the growing edge AI market, supported by an expanding portfolio of 61 issued and pending patents that enhances its competitive positioning.
The most recent analyst rating on (AU:BRN) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings has notified the market of the issue of 879,061 new fully paid ordinary shares following the conversion or exercise of previously unquoted options or other convertible securities. The additional shares, effective from 10 November 2025, modestly increase the company’s share base and reflect the uptake of equity-based instruments, which may slightly dilute existing shareholders while providing the company with potential capital and aligning incentives for option or security holders.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.
BrainChip Holdings Ltd has notified the market that 1,666,190 restricted stock units (RSUs) under the ASX security code BRNAM have lapsed after the conditions attached to those securities were not met or became incapable of being satisfied as of 3 October 2025. The cessation of these conditional equity rights reduces the company’s potential future share issuance, marginally limiting dilution for existing shareholders and slightly tightening BrainChip’s issued capital structure, though with no immediate operational impact disclosed in the filing.
The most recent analyst rating on (AU:BRN) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on BrainChip Holdings stock, see the AU:BRN Stock Forecast page.